cannabicitran

Cannabicitran (CBT) is a rare, non-psychoactive cannabinoid found in trace amounts in the *Cannabis sativa* plant. Structurally, it is characterized by a cyclic ether ring and is considered a minor cannabinoid within the phytocannabinoid family. InMed Pharmaceuticals, through its subsidiary BayMedica, has commercialized cannabicitran using a proprietary synthetic manufacturing process, targeting the health and wellness sector as a B2B ingredient. While research into its specific pharmacological profile is less extensive than that of major cannabinoids like THC or CBD, historical studies have suggested potential therapeutic applications in reducing intraocular pressure, making it a subject of interest for glaucoma research. It is currently marketed primarily as a high-purity ingredient for consumer health products.

Other names

cannabicitranCBTCitra-cannabinoid